Accommodating intraocular lens device

Information

  • Patent Grant
  • 10842616
  • Patent Number
    10,842,616
  • Date Filed
    Monday, May 2, 2016
    8 years ago
  • Date Issued
    Tuesday, November 24, 2020
    3 years ago
Abstract
An intraocular lens (IOL) device comprising a first lens, a second lens and a circumferential haptic. The first lens comprises a pair of opposing and deformable surfaces and a cavity defined therebetween. The first lens has a first lens diameter. The second lens has a second lens diameter. The circumferential haptic has an outer peripheral edge and couples the first lens and the second lens. A main IOL cavity is defined by the circumferential haptic, the first lens and the second lens. The IOL device is resiliently biased to an unaccommodated state, characterized by the IOL device having a first diameter d1 in the absence of radial compressive forces exerted on the outer peripheral edge. The IOL device actuates to an accommodated state being characterized by a second diameter d2 in response to radial compressive forces exerted on the outer peripheral edge, wherein d1>d2.
Description
FIELD OF THE INVENTION

The invention relates generally to an accommodating intraocular lens device and, more particularly, to an accommodating intraocular lens device configured for implantation in a lens chamber of a subject's eye.


BACKGROUND

Surgical procedures on the eye have been on the rise as technological advances permit for sophisticated interventions to address a wide variety of ophthalmic conditions. Patient acceptance has increased over the last twenty years as such procedures have proven to be generally safe and to produce results that significantly improve patient quality of life.


Cataract surgery remains one of the most common surgical procedures, with over 16 million cataract procedures being performed worldwide. It is expected that this number will continue to increase as average life expectancies continue to rise. Cataracts are typically treated by removing the crystalline lens from the eye and implanting an intraocular lens (“IOL”) in its place. As conventional IOL devices are primarily focused for distance visions, they fail to correct for presbyopia and reading glasses are still required. Thus, while patients who undergo a standard IOL implantation no longer experience clouding from cataracts, they are unable to accommodate, or change focus from near to far, from far to near, and to distances in between.


Surgeries to correct refractive errors of the eye have also become extremely common, of which LASIK enjoys substantial popularity with over 700,000 procedures being performed per year. Given the high prevalence of refractive errors and the relative safety and effectiveness of this procedure, more and more people are expected to turn to LASIK or other surgical procedures over conventional eyeglasses or contact lens. Despite the success of LASIK in treating myopia, there remains an unmet need for an effective surgical intervention to correct for presbyopia, which cannot be treated by conventional LASIK procedures.


As nearly every cataract patient also suffers from presbyopia, there is convergence of market demands for the treatment of both these conditions. While there is a general acceptance among physicians and patients of having implantable intraocular lens in the treatment of cataracts, similar procedures to correct for presbyopia represent only 5% of the U.S. cataract market. There is therefore a need to address both ophthalmic cataracts and/or presbyopia in the growing aging population.


BRIEF SUMMARY

The intraocular lens (IOL) device described herein generally comprise two lens portions. In a preferred embodiment, a first lens portion provides most, if not all, of the accommodative power and a second base lens provides most, if not all, of the corrective refractive power that is needed by a particular patient. Because the first lens portion must provide an accommodative power, it must respond by either changing shape or by displacement along an optical axis in response to the contraction and relaxation of the ciliary muscles which control the eye's natural ability to accommodate. To that end, the first lens portion may be provided as an elastically deformable lens chamber that is filled with a fluid or gel. In contrast to the elastically deformable lens chamber, the base lens is configured to not readily deform or change its curvature in response to the radially compressive forces exerted on the circumferential edge. The transfer of the radially compressive forces onto the lens chamber may be accomplished by incorporating one or more of the following features in the IOL: (1) the opposing sides of the lens chamber having a reduced thickness as compared to the base lens, (2) a hinge disposed between the base lens and the peripheral portion, (3) the lens chamber being made of a material having a lower Young's modulus than the base lens, and/or (4) the base lens being made of a substantially rigid material.


In one embodiment, an intraocular lens (IOL) device is provided. The IOL comprises a first lens comprising a pair of opposing and deformable surfaces and a cavity defined therebetween, the first lens having a first lens diameter, a second lens having a second lens diameter, and a circumferential haptic having an outer peripheral edge, the circumferential haptic coupling the first lens and the second lens. A main IOL cavity is defined by the circumferential haptic, the first lens and the second lens. The IOL device is resiliently biased to an unaccommodated state being characterized by the IOL device having a first diameter d1 in the absence of radial compressive forces exerted on the outer peripheral edge. The IOL device actuates to an accommodated state characterized by a second diameter d2 in response to radial compressive forces exerted on the outer peripheral edge, wherein d1>d2.


In accordance with a first aspect, the first lens is a biconvex lens.


In accordance with a second aspect, the cavity is fully enclosed.


In accordance with a third aspect, the IOL further comprises a gel in the cavity. The gel preferably has a refractive index of 1.46 or greater, preferably 1.48 or greater and most preferably 1.55 or greater. The gel preferably has a Young's modulus of 10 psi or less, preferably 5 psi or less, and more preferably 1 psi or less. In a particularly preferred embodiment, the gel has a Young's modulus of 0.5 psi or less, preferably 0.25 psi or less, and most preferably 0.01 psi or less. The gel preferably is a highly-branched polymer, preferably cross-linked silicone.


In accordance with a fourth aspect, the second lens is a one of a plano-convex lens, a bi-convex lens and a positive meniscus lens.


In accordance with a fifth aspect, the second lens is substantially more rigid than the first lens.


In accordance with a sixth aspect, the IOL further comprises a hinge disposed between the circumferential haptic and the second lens. In a preferred embodiment, in the presence of the compressive forces on the peripheral edge, the hinge directs a substantial portion of the compressive forces onto the first lens to cause a greater proportionate reduction in the first lens diameter to be reduced proportionately than in the second lens diameter.


In accordance with a seventh aspect, each of the opposing and deformable surfaces of the first lens has a thickness that is 50% or less of the second lens, preferably 25% or less of the second lens, and more preferably, 10% or less of the second lens.


In accordance with an eighth aspect, the IOL further comprises one or both of a plurality of apertures disposed on the circumferential haptic and a circumferential channel defined within the circumferential haptic. The plurality of apertures may be in fluid communication with the main IOL cavity. The plurality of apertures may be in fluid communication with both the circumferential channel and the main IOL cavity.


In accordance with a ninth aspect, the IOL device further comprises a plurality of raised bumps, wherein at least one of the plurality of raised bumps is positioned adjacent to each one of the plurality of apertures.


In accordance with a tenth aspect, the IOL device further comprises a plurality of troughs, at least one of the plurality of troughs extending radially inward from each one of the plurality of apertures to facilitate fluid flow into the apertures.


In accordance with an eleventh aspect, the circumferential haptic comprises a plurality of radial arms coupling the second lens, the plurality of radial arms defining apertures therebetween to permit fluid communication with the main cavity.


In accordance with a twelfth aspect, the circumferential haptic comprises a third circumferential cavity disposed peripherally of the main IOL cavity.


In accordance with a thirteenth aspect, the opposing surfaces of the first lens are displaced away from each other upon the application of a radial force along the circumferential haptic. The opposing surfaces comprises central and peripheral regions and a gradually increasing thickness profile from the peripheral to the central regions.


In another embodiment, an IOL is provided. The IOL comprises a first lens made of an elastic and deformable material having a first Young's modulus, a second lens in spaced relation to the first lens along a central optical axis and a circumferential portion encircling the first and second lens, the circumferential portion comprising an outer peripheral edge. At least one of a portion of the second lens and a portion of the circumferential portion is made of a material having a second Young's modulus. The first Young's modulus is less than the second Young's modulus.


In accordance with a first aspect, only the second lens is made of the material having the second Young's modulus.


In accordance with a second aspect, only the portion of the circumferential portion is made of the material having the second Young's modulus.


In accordance with a third aspect, the first Young's modulus is about 100 psi or less.


In accordance with a fourth aspect, the second Young's modulus is about 100 psi or greater.


In accordance with a fifth aspect, the second Young's modulus is about 150 psi or greater.


In accordance with a sixth aspect, the first lens comprises a pair of opposing and deformable surfaces and a cavity defined therebetween, the first lens having a first lens diameter and wherein a main IOL cavity is defined between the first lens, the second lens and the circumferential portion.


In accordance with a seventh aspect, the IOL further comprises a hinge disposed on the second lens outside of the active optical area.


In accordance with an eighth aspect, the first lens is comprised of two opposing surfaces which are displaced away from each other upon the application of a radial force along a peripheral edge. The two opposing surfaces each having central and peripheral regions, wherein the central region has a thickness that is at least 2 times, preferably at least three times, and most preferably at least four times greater than a thickness of the peripheral region.


In a further embodiment, an IOL is provided. The IOL comprises a first lens, a second lens in spaced relation to the first lens and a circumferential haptic coupling the first and second lens. The first lens comprises opposing sides and an enclosed cavity between the opposing sides. The opposing sides each have central and peripheral regions, the central region being disposed around an optical axis, the peripheral region being disposed around the central region. The central region is at least two times thicker than the peripheral region. The second lens in spaced relation to the first lens, the second lens having a thickness that is greater than either one of the opposing sides of the first lens. A circumferential haptic has an outer peripheral edge configured for engagement with a capsular bag of an eye when the IOL is implanted. A main IOL cavity is defined by the circumferential haptic, the first lens and the second lens.


In accordance with a first aspect, the central region is at least three times thicker than the peripheral region.


In accordance with a second aspect, the central region is at least four times thicker than the peripheral region.


In accordance with a third aspect, the enclosed cavity of the first lens comprises a gel having a first refractive index.


In accordance with a fourth aspect, the opposing sides of the first lens has a second refractive index that is less than the first refractive index of the gel.


In accordance with a fifth aspect, the gel is a vinyl-terminated phenyl siloxane.


In accordance with a sixth aspect, the gel has a Young's modulus of 0.25 psi or less, preferably 0.01 psi or less.


Other objects, features and advantages of the described preferred embodiments will become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications.





BRIEF DESCRIPTION OF THE DRAWINGS

Illustrative embodiments of the present disclosure are described herein with reference to the accompanying drawings, in which:



FIGS. 1A-1B are perspective and side cross-sectional views, respectively, of an embodiment of a dual-cavity IOL device.



FIG. 2 is a perspective cross-sectional view of another embodiment of a dual-cavity IOL device having holes disposed on the top surface.



FIGS. 3A-3B are front and perspective cross-sectional views of another embodiment of a dual-cavity IOL device having through-holes disposed through the top and bottom surfaces in communication with the main cavity.



FIG. 4 is a perspective cross-sectional view of another embodiment of a dual-cavity IOL device having through-holes disposed through the top and bottom surfaces and which are not in fluid communication with the main cavity.



FIGS. 5A-5B are perspective cross-sectional views of another embodiment of a dual-cavity IOL device comprising arc-shaped cutouts on the bottom surface to provide a fluid communication with the main cavity.



FIGS. 6A-6B are perspective cross-sectional and rear views of another embodiment of a dual-cavity IOL device comprising arch-shaped cutouts on the bottom surface and a plurality of peripheral through holes in communication with a circumferential channel.



FIG. 7A-7B are top perspective and cross-sectional views of another embodiment of a dual-cavity IOL device comprising a plurality of raised protrusions adjacent through-holes which are in communication with the main cavity and circumferential channel.



FIG. 8A-8B are top perspective and cross-sectional views of another embodiment of a dual-cavity IOL device comprising a plurality of troughs adjacent through-holes which are in communication with the main cavity and circumferential channel.



FIG. 9 is a partial cross-sectional view of an embodiment of the IOL device, cut away along the optical axis A-A.



FIGS. 10A-10B are cross-sectional views of further embodiments of the IOL device.



FIG. 11A depicts the human eye with the lens material removed following a capsulorhexis.



FIGS. 11B-11C depict the implanted IOL device in the unaccommodated and accommodated states, respectively.





Like numerals refer to like parts throughout the several views of the drawings.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Specific, non-limiting embodiments of the present invention will now be described with reference to the drawings. It should be understood that such embodiments are by way of example and are merely illustrative of but a small number of embodiments within the scope of the present invention. Various changes and modifications obvious to one skilled in the art to which the present invention pertains are deemed to be within the spirit, scope and contemplation of the present invention as further defined in the appended claims.



FIGS. 1A-1B depicts a basic structure of an embodiment of the accommodating intraocular lens (IOL) 100. The IOL 100 is depicted as comprising an elastically deformable lens chamber 110, a base lens 150, and a lens periphery 170 coupling the lens chamber 110 and the base lens 150. The elastically deformable lens chamber 110 provides most, if not all, of the accommodative power by deforming or changing in curvature in response to the radially compressive forces that are exerted onto the IOL 100 during accommodation. The base lens 150 provides most, if not all, of the corrective refractive power that is required by a particular patient and is not required to deform or change in shape or curvature. Thus, the lens chamber 110 and the base lens 150 cooperate to restore both a patient's vision and natural range of accommodation.


The lens chamber 110 is made of an elastically deformable material and comprises opposing sides 112 and 114 that are joined together at the periphery of the lens chamber 110 to define a bi-convex exterior shape and an internal enclosed cavity 120. Each of the opposing sides 112 and 114 comprise a central region 112a, 114a and a peripheral region 112b, 114b and a gradient of thickness that increases radially from the peripheral region 112b, 114b to the central region 112a, 114a. This thickness profile is intended to encourage deformation of the opposing sides 112, 114 away from one another and to permit the opposing sides to bulge and increase its curvature in opposing directions along an optical axis A-A without causing the membrane to buckle about the central region 112a, 114a. Thus, while the conventional wisdom suggests that a greater degree of deformation and outward bulging would be achieved with the opposite thickness profile (e.g., a thickness profile that decreases radially from the peripheral region 112b, 114b to the central region 112a, 114a), such a thickness profile is more likely to cause the lens chamber 110 to buckle or collapse inwardly about the central region 112a, 114a upon the application of a radially compressive force once implanted in a patient's eye. During accommodation, the application of radially compressive forces may cause an internal vacuum to develop inside the lens chamber 110, thereby causing the opposing sides 112, 114 to buckle inwardly.


Thus, in a particularly preferred embodiment, the opposing sides have a gradually increasing thickness from the peripheral regions 112b, 114b, to the central region 112a, 114a. In a preferred embodiment, the central region 112a, 114a, as measured along the optical axis A-A, has a thickness that is two times or more, preferably three times or more, and most preferably four times or more than the thickness of the peripheral region 112b, 114b, as measured just adjacent to the area where the opposing sides 112, 114 join at the peripheral region. In another preferred embodiment, the point of greatest thickness in the central region 112a, 114a and the point of least thickness in the peripheral regions 112b, 114b is characterized as having a thickness ratio of 2:1 or greater, preferably 3:1 or greater, and most preferably 4:1 or greater. In one embodiment, the central region 112a, 114a, as measured along the optical axis A-A, comprises an area of thickness that is about 100 microns, preferably about 200 microns, and the peripheral region 112b, 114b comprises an area of thickness that is about 50 microns as measured just adjacent to the area where the opposing sides 112, 114 join at the peripheral region. While the thickness profile is described in relation to FIGS. 1A-1B, it is understood that the same or a substantially similar thickness profile may be provided for all of the IOL devices depicted and described herein.


The base lens 150 is coupled to the lens chamber 110 via a lens periphery 170. The base lens 150 may be a positive lens that provides convergent power, such as a bi-convex, plano-convex or a positive meniscus lens. Alternatively, the base lens 150 may be a negative lens that provides divergent power, such as a bi-concave, plano-concave or a negative meniscus lens. The base lens 150 depicted in FIGS. 1A-1B is a positive meniscus lens.


The base lens 150 is preferably more rigid than the opposing sides 112, 114 of the lens chamber 110. The greater rigidity may be imparted by providing a base lens 150 having a thickness that is significantly greater than the thicknesses of the opposing sides 112, 114 of the lens chamber 110. Alternatively or in addition to providing a greater thickness, the base lens 150 may be made of a different or stiffer material having a higher elastic Young's modulus as compared to the lens chamber 110. The base lens 150 preferably does not substantially change its shape and curvature in response to the radially-compressive accommodative force applied onto the peripheral edge 180 of the lens periphery 170. Instead, the radially compressive accommodative forces are transferred onto the lens chamber 110 to cause the desired deforming changes.


In a preferred embodiment, the base lens 150 is substantially thicker than one of the opposing sides 112, 114 of the lens chamber 110, as measured along the optical axis A-A. In a preferred embodiment, the thickness of each one of the opposing sides 112, 114 of the lens chamber 110, as along the optical axis A-A depicted in FIGS. 1A-1B and 9, is less than ½, preferably less than ⅓, preferably less than ¼, and most preferably less than ⅕ of the thickness of the base lens 150 at the central optical axis A-A. Because the base lens 150 is substantially thicker than either one of the opposing sides 112, 114 of the lens chamber 110, the base lens 150 has an effective Young's modulus that is substantially greater than either one of the opposing sides 112, 114 of the lens chamber 110. While FIGS. 1A-1B and 9 depict the relative thickness of the opposing sides 112, 114 of the lens chamber 110 and the base lens 150 for IOL 100, it is understood that all of the IOL devices disclosed herein may have the same or similar thickness profile with respect to the lens chamber 110 and the base lens 150.


The lens chamber 110 and the base lens 150 are coupled together by a lens periphery 170. The lens periphery 170 comprises a circumferential edge 180 configured to engage a circumferential region of the capsular bag of the eye. As depicted in FIGS. 11A-11C, the circumferential region 52 is where the capsular bag 40 is coupled to the zonules 50, generally at a location where the density of the zonules 50 is the greatest. The zonules 50, in turn, couple the capsular bag 40 to the ciliary muscles 60 which contract and relax to provide a range of accommodation. While FIGS. 11B and 11C depict a particularly preferred embodiment in which an IOL 100 is implanted with the lens chamber 110 being oriented anteriorly within the lens capsule 40 of the eye, it is understood that the IOL 100 may also be implanted with the lens chamber 110 being oriented posteriorly within the lens capsule 40 of the eye.


The lens periphery 170 comprises a radial portion 172 and a circumferential hinge 174 that cooperate together to transmit a significant portion, if not most, of the radially compressive forces exerted onto the circumferential edge 180 onto the lens chamber 110 and away from the base lens 150. Referring back to FIGS. 1A-1B, the radial portion 172 extends radially inwardly from the lens periphery 170 to the lens chamber 110 and the hinge 174 is disposed between the lens periphery 170 and the base lens 150. Both the radial portion 172 and the hinge 174 cooperate to maximize the extent to which the radially-compressive accommodative forces applied to the peripheral edge 180 are transmitted to the lens chamber 110. The greater the force transmitted to the lens chamber 110, the greater the deformation and change of curvature of the opposing sides 112, 114 of the lens chamber 110.


The lens periphery 170 may be solid and thickened as compared to the base lens 150, as depicted in FIGS. 1A-1B and 9. Alternatively, the lens periphery 170 may comprise a hollow space or a circumferential channel to reduce the delivery profile of the IOL, as depicted in FIGS. 2, 3A, 3B, 4, 6, 7, and 8. Because the IOL 100 is implanted into a relatively small incision size, it must be rolled up to assume a delivery profile that is at least as small as the incision size.


The circumferential hinge 174 is provided as a thinned or grooved area disposed in the lens periphery 170 and surrounding the base lens 150. The circumferential hinge 174 permits the lens periphery 170 to pivot radially inwardly towards the lens chamber 110 such that the radially compressive forces applied to the circumferential edge 180 are directed substantially along the radial portion 172 and applied to the lens chamber 110, as opposed to being applied to the base lens 150, which is configured to generally resist deformation (See FIG. 11C). Thus, the radial portion 172 is itself preferably sufficiently rigid in order to substantially transmit the radial compressive force onto the lens chamber 110. In a preferred embodiment, the hinge 174 is provided both peripherally and circumferentially around the base lens 150 as a thinned area or as a groove.



FIGS. 11B and 11C depicts the configuration of the IOL 100 in the absence of a radial compressive force applied to the circumferential peripheral edge 180 (FIG. 11B, an unaccommodated eye) and in the presence of a radial compressive force applied to the circumferential peripheral edge 180 (FIG. 11C, an accommodated eye) in which the peripheral edge 180 tilts in the direction C about the hinge 174, transmitting the radial compressive forces onto the lens chamber 110, and thereby causing the opposing sides 112, 114 of the lens chamber 110 to be displaced apart from one another and increase in curvature.


The features described herein which are intended to maximize the extent to which the radially compressive forces are transmitted to a lens chamber 110 and thus provide a large range of accommodation. The IOLs described herein may further be made of a material that does not resist deformation or is characterized as having a low Young's modulus. The IOLs may be made of a single material or, alternatively, different portions of the IOL may be made of different materials having differing Young's modulus (see FIGS. 10A-10B).


In one preferred embodiment, at least the opposing sides 112, 114 of the lens chamber 110 is made of a material of sufficient mechanical strength to withstand physical manipulation during implantation, but is of sufficiently low Young's modulus so as to minimize its resistance to deformation. In a preferred embodiment, the opposing sides 112, 114 of the lens chamber 110 is made of a polymer having a Young's modulus of 100 psi or less, preferably 75 psi or less, and most preferably 50 psi or less. In one preferred embodiment, the remaining portions of the IOL 100 (e.g., the base lens 150, the peripheral portion 170) has a Young's modulus that is greater than the Young's modulus of the walls 112, 114, of the lens chamber 110. The walls 112, 114 of the lens chamber 110 may be a polymer, preferably a silicone polymer and, more preferably a phenyl siloxane, such as a vinyl-terminated phenyl siloxane or a vinyl-terminated diphenyl siloxane. In order to impart sufficient mechanical strength, the polymer may be crosslinked, reinforced with fillers, or both. The fillers may be a resin or silica that have been functionalized to react with the polymer.


The opposing sides 112, 114 of the lens chamber 110 defines an enclosed cavity 120 that is filled with a fluid or gel having specific physical and chemical characteristics to enhance the range of refractive power provided by the IOL during accommodation. The fluid or gel is selected such that it cooperates with the walls 112, 114 of the lens chamber 110 in providing a sufficient range of accommodation of up to at least 3 diopters, preferably up to at least 5 diopters, preferably up to at least 10 diopters and most preferably up to at least 15 diopters. In a preferred embodiment, the enclosed cavity 120 is filled with the fluid or gel before implantation of the IOL 100 into the capsular bag 40 of the eye and, in a more preferred embodiment, the cavity 120 is filled with the fluid or gel in the manufacture of the IOL 100.


In one preferred embodiment the enclosed cavity 120 is filled with a fluid, such as a gas or a liquid, having low viscosity at room temperature and a high refractive index. In a preferred embodiment, the fluid is a liquid having a viscosity of 1,000 cP or less at 23° C. and a refractive index of at least 1.46, 1.47, 1.48, or 1.49. The fluid may be a polymer, preferably a silicone polymer, and more preferably a phenyl siloxane polymer, such as a vinyl-terminated phenyl siloxane polymer or a vinyl-terminated diphenyl siloxane polymer. Preferably, in embodiments where the fluid is made of a polymer, the polymer is preferably not crosslinked and that the polymer may be linear or branched. Where the fluid is a vinyl-terminated phenyl siloxane polymer or diphenyl siloxane polymer, the vinyl groups may be reacted to form other moieties that do not form crosslinkages.


In accordance with one embodiment, fluid may be a polyphenyl ether (“PPE”), as described in U.S. Pat. No. 7,256,943, entitled “Variable Focus Liquid-Filled Lens Using Polyphenyl Ethers” to Teledyne Licensing, LLC, the entire contents of which are incorporated herein by reference as if set forth fully herein.


In accordance with another embodiment, the fluid may be a fluorinated polyphenyl ether (“FPPE”). FPPE has the unique advantage of providing tunability of the refractive index while being a chemically inert, biocompatible fluid with low permeability in many polymers. The tunability is provided by the increasing or decreasing the phenyl and fluoro content of the polymer. Increasing the phenyl content will effectively increase the refractive index of the FPPE, whereas increasing the fluoro content will decrease the refractive index of the FPPE while decreasing the permeability of the FPPE fluid through the walls 112, 114 of the lens chamber 110.


In another preferred embodiment, the enclosed cavity 120 is filled with a gel. The gel preferably has a refractive index of at least 1.46, 1.47, 1.48, or 1.49. The gel may also preferably have a young's modulus of 20 psi or less, 10 psi or less, 4 psi or less, 1 psi or less, 0.5 psi or less, 0.25 psi or less and 0.01 psi or less. In a preferred embodiment, the gel is a crosslinked polymer, preferably a crosslinked silicone polymer, and more preferably a crosslinked phenyl siloxane polymer, such a crosslinked vinyl-terminated phenyl siloxane polymer or a vinyl-terminated diphenylsiloxane polymer. Other optically clear polymer liquids or gels, in addition to siloxane polymers, may be used to fill the cavity 120 and such polymers may be branched, unbranched, crosslinked or uncrosslinked or any combination of the foregoing.


A gel has the advantages of being extended in molecular weight from being crosslinked, more self-adherent and also adherent to the walls or opposing sides or walls 112, 114 of the lens chamber 110 than most liquids. This makes a gel less likely to leak through the walls 112, 114 of the lens chamber 110. In order to obtain the combination of accommodative power with relatively small deformations in the curvature of the walls 112, 114 of the lens chamber 110, the gel is selected so as to have a high refractive index while being made of an optically clear material that is characterized as having a low Young's modulus. Thus, in a preferred embodiment, the gel has a refractive index of 1.46 or greater, preferably 1.47 or greater, 1.48 or greater and most preferably 1.49 or greater. At the same time, the gel preferably has a Young's modulus of 10 psi or less, preferably 5 psi or less, and more preferably 1 psi or less. In a particularly preferred embodiment, the gel has a Young's modulus of 0.5 psi or less, preferably 0.25 psi or less, and most preferably 0.01 psi or less. It is understood that at lower Young's modulus, the gel will present less resistance to deformation and thus the greater the deformation of the walls 112, 114 of the lens chamber 110 for a given unit of applied force.


In particularly preferred embodiment, the gel is a vinyl-terminated phenyl siloxane that is produced based on one of the four formulas provided as follows:


Formula 1:

    • 100 parts 20-25 mole % vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer (Gelest PDV 2335).
    • 3 ppm platinum complex catalyst
    • 0.35 pph of phenyl siloxane hydride crosslinker (Nusil XL-106)
    • Young's modulus of elasticity=0.0033 psi


Formula 2:

    • 100 parts 20-25 mole % vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer (Gelest PDV 2335).
    • 3 ppm platinum complex catalyst
    • 0.4 pph of phenyl siloxane hydride crosslinker (Nusil XL-106)
    • Young's modulus of elasticity=0.0086 psi


Formula 3:

    • 100 parts 20-25 mole % vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer (Gelest PDV 2335).
    • 3 ppm platinum complex catalyst
    • 0.5 pph of phenyl siloxane hydride crosslinker (Nusil XL-106)
    • Young's modulus of elasticity=0.0840 psi


Formula 4:

    • 100 parts 20-25 mole % vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer (Gelest PDV 2335).
    • 3 ppm platinum complex catalyst
    • 0.6 pph of phenyl siloxane hydride crosslinker (Nusil XL-106)
    • Young's modulus of elasticity=2.6 psi


The walls 112, 114 of the lens chamber 110 and the fluid or gel contained within the lens cavity 120 are preferably selected so as to prevent or reduce the likelihood of the fluid or gel migrating outside of the walls 112, 114 of the lens chamber 110. Thus, in a preferred embodiment, one or both of the walls 112, 114 of the lens chamber 110 and the fluid or gel is/are selected from biocompatible materials that optimize the resistance to permeability of the fluid or gel across the walls 112, 114 of the lens chamber 110.


One method of decreasing the permeability of the gel contained inside the cavity 120 across the walls 112, 114 of the lens chamber 110 is to provide a gel that is cross-linked. The degree of cross-linking, however, must be selected and controlled such that, on the one hand, the walls 112, 114 of the lens chamber 110 and the gel have a sufficiently low Young's modulus to minimize the resistance of the walls 112, 114 of the lens chamber 110 to deformation and, on the other hand, to minimize the permeation of the gel across the walls 112, 114 of the lens chamber 110. Thus, in a preferred embodiment, longer chain polymers that are lightly cross-linked, such as those used for silicone gels, starting with monomers having molecular weights that are greater than 35,000 daltons, preferably greater than 50,000 daltons and, most preferably, at least 70,000 daltons are desired.


In another preferred embodiment, a gel is used having low permeability extractables. Such gels may be formulated by using long chain polymers that are branched.


In a preferred embodiment, one or both of the lens chamber walls 112, 114 and the gel is made of homo- or co-polymers of phenyl-substituted silicones.


For the lens chamber walls 112, 114, the crosslinked homo- or co-polymers preferably have a diphenyl content of 5-25 mol %, preferably 10-20 mol % and more preferably 15-18 mol %. Alternatively, for the lens chamber walls 112, 114, the homo- or co-polymers preferably have a phenyl content of 10-50 mol %, preferably 20-40 mol %, and more preferably 30-36 mol %.


For the gel, the homo- or co-polymers preferably have a diphenyl content of 10-35 mol %, preferably 15-30 mol % and more preferably 20-25 mol %. Alternatively, for the gel, the homo- or co-polymers preferably have a phenyl content of 20-70 mol %, preferably 30-60 mol % and more preferably 40-50 mol %.


In a particularly preferred embodiment, the lens chamber walls 112, 114 are made of a crosslinked phenyl siloxane having a diphenyl content of about 15-18 mol % or a phenyl content of about 30-36 mol % and the gel is made of a phenyl siloxane having a diphenyl content of about 20-25 mol % or a phenyl content of about 40-50 mol %. The lens chamber walls 112, 114 are understood to be more crosslinked than the gel.


In a particularly preferred embodiment, the lens chamber walls 112, 114 are made of a vinyl-terminated phenyl siloxane, most preferably a crosslinked vinyl-terminated phenyl siloxane. Reinforcing agents, such as silica, may also be included in a range 10-70 mol %, preferably 20-60 mol % and most preferably 30-50 mol %.


The walls 112, 114 of the lens chamber 110 and the fluid or gel contained within the lens cavity 120 are also preferably selected so as to increase the range of accommodative power that is provided by the lens chamber 110. In one preferred embodiment, the walls 112, 114 of the lens chamber 110 are made of a material having a lower refractive index than the fluid or gel contained in the enclosed cavity. In one preferred embodiment, the refractive index of the lens walls 112, 114 of the chamber 110 is 1.38 and the refractive index of the gel or fluid is 1.49.


The differential refractive indices provided by the lens chamber walls 112, 114 and the gel or liquid contained within the chamber 120 may be provided by the differences in the materials or the composition of the materials used for the lens chamber walls 112, 114 and the gel or liquid.


In one embodiment, both the lens chamber walls 112, 114 and the gel or liquid is made of a phenyl siloxane having different diphenyl or phenyl content. In a preferred embodiment, the lens chamber walls 112, 114 has a diphenyl or phenyl content that is less than that for the gel or liquid. In another preferred embodiment, the walls 112, 114 of the lens chamber 110 may be made of a cross-linked vinyl-terminated phenyl siloxane having a diphenyl content of 15-18 mol % or a phenyl content of 30-36 mol % and the gel contained within the walls 112, 114 of the lens chamber 110 may be made of a vinyl-terminated phenyl-siloxane having a diphenyl content of 20-25 mol % or a phenyl content of 30-36 mol %.


In another embodiment, the differential refractive indices may be provided by providing a dimethyl siloxane for the lens chamber walls 112, 114 and the gel may be a phenyl siloxane having a high diphenyl or phenyl content. In a preferred embodiment, the diphenyl content is at least 20 mol %, at least 25 mol %, at least 30 mol %, at least 35 mol %, and at least 40 mol %. Alternatively, the phenyl content is at least 40 mol %, at least 50 mol %, at least 60 mol %, at least 70 mol %, and at least 80 mol %.


In a further embodiment, the differential refractive indices may be provided by a crosslinked fluoro siloxane, such as a 3,3,3-trifluoropropylmethyl siloxane and the gel may be a phenyl siloxane having a high diphenyl or phenyl content. In a preferred embodiment, the diphenyl content is at least 20 mol %, at least 25 mol %, at least 30 mol %, at least 35 mol %, and at least 40 mol %. Alternatively, the phenyl content is at least 40 mol %, at least 50 mol %, at least 60 mol %, at least 70 mol %, and at least 80 mol %.


Now turning back to FIGS. 1A-1B, a main cavity 130 is defined between the lens chamber 110, the base lens 150 and the lens periphery 170. The main cavity 130 is preferably filled with a fluid or gel. The fluid or gel in the main cavity 130 may be the same as the fluid or gel contained in the enclosed cavity 120. In a preferred embodiment, the fluid is a saline solution and the main cavity 130 is filled with the saline solution after implantation of the IOL in the capsular bag of the eye.


Filling the main cavity 130 after implantation of the IOL into the capsular bag will permit the IOL to take on a significantly smaller delivery profile such that the IOL may be rolled up and inserted through a relatively small incision. In a preferred embodiment, the incision size is less than 6 mm, preferably less than 5 mm, most preferably less than 4 mm and even most preferably less than 3 mm.


In embodiments where the main cavity 130 is filled with a fluid or gel after implantation, a valve (not shown) is preferably disposed on the IOL to permit injection of the fluid or gel into the main cavity 130 after implantation. The valve may be a one-way valve that permits injection of fluid or gel into the main cavity 130 but prevents the fluid or gel from exiting the main cavity 130. The valve is preferably disposed on the surface of the IOL that is facing in the anterior direction after it has been implanted in the eye. It is understood that the valve, however, is preferably not disposed on either one of the opposing sides 112, 114 so as to avoid disrupting the integrity of the lens chamber 110 which may house the same of different fluid or gel.


In a preferred embodiment, the fluids or gels in the respective enclosed cavity 120 and the main cavity 130 are completely segregated from one another. In one preferred embodiment, the enclosed cavity 120 and the main cavity 130 may have a different fluid and/or gel. In another preferred embodiment, one of the enclosed cavity 120 and the main cavity 130 may comprise one of a fluid or gel and the other one of the enclosed cavity 120 and the main cavity 130 may comprise the other one of a fluid or gel. In a preferred embodiment, there is no fluid exchanged between the enclosed cavity 120 and the main cavity 130.


The IOL 100 is intended to be implanted in a capsular bag 40 of the eye and centered about an optical axis A-A (See FIGS. 11A-11C). The lens chamber 110 and the base lens 150 are dimensioned to extend to or beyond the effective optical zone B-B as defined about the optical axis A-A of a patient's eye. The effective optical zone B-B is generally the largest possible opening through which light can enter the eye and thus is controlled by the largest effective diameter of the pupil 30 when completely dilated. This diameter is typically about 4-9 mm. Therefore, in a preferred embodiment, the diameters of the lens chamber 110 and the base lens 150 is preferably at least 4 mm, at least 5 mm, at least 6 mm, at least 7 mm, at least 8 mm and at least 9 mm.


As previously indicated, either one or both of the enclosed cavity 120 of the lens chamber 110 and/or the main cavity 130 is/are filled with a fluid or gel. The fluid may be a gas, a liquid. The fluid or gel preferably is characterized as having a sufficiently high refractive index such that the lens chamber 110 provides a range of accommodation in response to small changes in the curvature of the opposing sides 112, 114.


Because the IOL 100 is resiliently biased such that the opposing sides 112, 114 of the lens chamber 110 are substantially flat or have minimal curvature, small changes in the curvature of the opposing sides 112, 114 will lead to proportionately greater changes in the refractive power of the lens. Thus, the lens chamber 110, in combination with the base lens 150, can provide a change in the optical power of up to at least 3 diopters, preferably up to at least 5 diopters, preferably up to at least 10 diopters and most preferably up to 15 diopters in response to the accommodative forces (e.g., radially compressive forces) exerted on the implanted IOL.



FIG. 2 depicts another embodiment of the IOL 200. The IOL 200 is similar in many respects with the IOL 100 of FIGS. 1A-1B in that it comprises a lens chamber 210, a base lens 250 and a lens periphery 270 joining the lens chamber 210 and the base lens 250. The lens periphery 270 further comprises a circumferential edge 280. The IOL 200 differs from IOL 100 in that IOL 200 comprises a plurality of holes 202 disposed circumferentially along the top surface of the IOL 200 and externally around the lens chamber 210 and a circumferential channel 240 disposed within the lens periphery 270. The holes 202 are intended to provide a fluid exchange channel between the circumferential channel 240, the main cavity 230 and the exterior of the IOL 200. The accommodative forces of the eye's capsular bag will cause the IOL 200 to radially expand and compress which, in turn, will cause the aqueous fluid to enter and exit the main cavity 230 through the holes 202. In a preferred embodiment, the holes 202 are disposed symmetrically about the top surface of the IOL 200.



FIGS. 3A-3B depict another embodiment of the IOL 300 which comprises a plurality of through-holes 302 around the circumferential periphery of the IOL 300. The through-holes 302 differ from the holes 202 in FIG. 2 in that the through-holes are provided through both sides of the IOL 300 and the IOL 300 does not comprise a circumferential channel, whereas the holes 202 of the IOL 200 of FIG. 2 are only provided on the top surface of the IOL 200. The provision of through-holes 302 increase the efficiency with which the aqueous fluid fills and exits the main cavity 330.


Moreover, the through-holes 302 are dimensioned to be as large as can fit between the space between the circumferential edge 380 and the lens chamber 310. One advantage in the provision of numerous large through-holes 302 about the circumferential periphery is that it reduces the material bulk of the IOL 300 and permits it to take on a smaller delivery profile when it is folded and inserted into the capsular bag of the eye during implantation surgery. Thus, the IOL 300 will require a smaller incision for implantation into the capsular bag of the eye. It is understood, however, that the spacing 301 between the through-holes 302 must be sufficient to permit the transfer of force applied to the circumferential edge 380 onto the lens chamber 310. In a preferred embodiment, the spacing 301 is no more than ¼, preferably no more than ½, and most preferably no more than ¾ of the diameter of the through-holes 302.



FIG. 4 depicts another embodiment of the IOL 400 also comprising through-holes 402, except that the through-holes 402 do not provide a fluid exchange between the main cavity 430 and the exterior of the IOL 400. The IOL 400 is thus similar to the IOL 100 of FIGS. 1A-1B in that a valve is required such that the main cavity 430 of the IOL 400 may be filled after implantation into the capsular bag of the eye. The main function of the through-holes 402 in this embodiment is to reduce the bulk of the IOL 400 so as to provide a smaller delivery profile. Thus, once implanted, the fluid or gel in the lens cavity 420 and the main cavity 430 remain contained and the IOL 400 does not permit for fluid exchange between the fluid in the exterior of the IOL 400 and the fluid or gel in the main cavity 430. FIG. 4 differs from the IOLs depicted in the preceding figures (FIGS. 1-3) in that it depicts the shape of the IOL 400 when a radial force is applied to the peripheral edge so as to cause a the opposing sides of the cavity 420 to bulge apart from one another. It is noted that the IOL 400 must be dimensioned such that the lower wall of the lens cavity 420 does not contact the base lens 450 within a range of the radial force that would be expected during the accommodation of the eye.



FIGS. 5A-5B depict yet a further embodiment of the IOL 500 which comprises a plurality of arc-shaped cutouts 502. The arc-shaped cutouts 502 are configured to function to provide a fluid exchange between the main cavity 530 and the exterior of the IOL 500. The IOL 500 comprises radial arms 504 between the arc-shaped cutouts 502 to couple and support the base lens 550 to the lens periphery 570. In a preferred embodiment, the radial arms 504 comprise a hinge between the peripheral portion 570 and the base lens 550 that permits the radial arms 504 to bend or rock inwardly upon application of a force upon the circumferential edge 580 so that the force is transferred to radially compressing the lens chamber 510. The hinge may simply be a groove or an area of reduced material thickness that is disposed either on the internal, external or both internal and external surfaces of the radial arms 504. As with the other IOLs described herein, the IOL 500 returns to a radially-expanded state in the absence of a force applied upon the circumferential edge 580. The IOL 500 is resiliently biased to a flatter configuration as shown in FIG. 5A in the absence of radially-compressive forces being exerted on the circumferential edge 580, as when the eye is unaccommodated. The IOL 500 is radially compressible to reduce the overall diameter of the lens chamber 110 and thus cause opposing sides 512, 514 of the lens chamber 510 to increase its curvature upon the application of a radially compressing force onto the circumferential edge 580, as when the eye is accommodated. See, e.g., FIG. 4.



FIGS. 6A-6B depicts yet a further embodiment of the IOL 600 which comprises an internal circumferential channel 640 in addition to the enclosed cavity 620 and the main cavity 630. The circumferential through-holes 602 permit aqueous fluid flow into and out of the circumferential channel 640 and the arc-shaped cutouts 604 permit aqueous fluid flow into and out of the main cavity 630. Radial arms 606 couple the base lens 650 to the peripheral portion 670 and a hinge is disposed on the radial arm between the base lens 650 and the peripheral portion 670. Again, the presence of the internal circumferential channel 640 is intended to reduce the material bulk and thus to permit insertion of the IOL 600 through relatively smaller incisions.


The IOLs described herein are intended for implantation in a capsular bag of a patient's eye following performance of a capsulorhexis, in which a circular portion is removed from the anterior portion of the capsular bag.



FIG. 11A depicts the eye 10 following performance of a capsulhorexis and before implantation of an IOL. The eye 10 is depicted as comprising a cornea 20 through which the surgical incision is made to access the capsular bag 40. The diameter of the circular portion B-B removed from the capsular bag 40 depends upon each person's individual anatomy is typically in the range of from about 4 mm to about 9 mm. Here, the diameter 32 of the circular portion B-B removed from the capsular bag 40 corresponds roughly to the diameter of the pupil 30. Preferably, as much of the capsular bag 40 and its zonular connections 50 are maintained as possible. The zonules 50 couple the capsular bag 40 with the ciliary muscle 60 and transmit the accommodative forces to effectuate the curvature or shape changes of the capsular bag 40. Once the crystalline lens material is removed from the capsular bag 40, the IOL may be inserted and implanted such that the circumferential edge substantially engages the zonules 50 attached to the capsular bag 40. Additionally, the IOL is substantially centered along the optical axis A-A and engagement of the IOL with the zonules 50 is preferred to reduce the likelihood of decentration. In embodiments of the IOL comprising holes and through-holes, it is preferable that the holes and through-holes be located outside of the optical zone B-B. Moreover, the holes and through-holes should have rounded edges so as to prevent the perception of glare by the recipient.



FIGS. 7A-7B and 8A-8B depict an IOL 700 which is configured with raised protrusions 790 or troughs 795 adjacent to the through-holes 702 to create a space between the capsular bag and the through-holes 702 and to thereby ensure the free flow of the aqueous fluid in and out of the main cavity 730 and the circumferential channel 740.


The IOL 700 comprises three enclosed chambers: an enclosed lens chamber 720, a main cavity 730 and an internal circumferential channel 740. A plurality of circumferentially disposed through-holes 702 are sized to provide fluid exchange between both the main cavity 730 and the internal circumferential channel 740, on the one hand, and the exterior of the IOL 700, on the other hand. The fluid or gel in the lens chamber 720 remains contained within the lens chamber 720.


The IOL 700 further comprises arc-shaped cut-outs 704 and radial arms 706 disposed to couple the base lens 750 to the peripheral portion 770, in the same manner as depicted in FIGS. 6A-6B. The significant feature of IOL 700 is the presence of raised protrusions 790 (FIGS. 7A-7B) or troughs 795 (FIGS. 8A-8B) adjacent the through-holes 702. The raised protrusions 790 or troughs 795 are configured to ensure that the capsular bag does not form a seal over the through-holes 702 so as to impede or prevent the aqueous fluid from flowing freely in and out of the main cavity 730 and the circumferential channel 740.


As discussed above, the IOLs described herein are configured to transmit most, if not all, of the radially compressive forces exerted on the circumferential edge onto the lens chamber. In contrast to the elastically deformable lens chamber, the base lens is not configured to deform or change its curvature in response to the radially compressive forces exerted on the circumferential edge. The transfer of the radially compressive forces onto the lens chamber may be accomplished by incorporating one or more of the following features in the IOL: (1) the opposing sides of the lens chamber having a reduced thickness as compared to the base lens, (2) a hinge disposed between the base lens and the peripheral portion, (3) utilizing materials having different elastic moduli for the lens chamber and the base lens; and (4) the variation of refractive indices provided for the opposing sides of the lens chamber and the fluid or gel contained therein.



FIGS. 10A and 10B depict an IOL 800 which is constructed of at least two different elastomeric materials having different Young's modulus of elasticity, with at least the base lens 850 being made of a material having a higher Young's modulus than the lens chamber 810.



FIG. 10A depicts the IOL 800 as being constructed by assembling at least five (5) separately molded pieces, 801A, 802A, 803A, 804A, and 850. Thus, in addition to the two halves 801A, 803A of the lens chamber 810, The peripheral portion of the IOL 800 is provided in two ring portions 802A, 804A. The first ring portion 802A surrounding the lens chamber 810 has a higher elastic Young's modulus than the second ring portion 804A surrounding the base lens 850. In a preferred embodiment, the two halves 801A, 803A of the lens chamber 810 and the second ring portion 803A has a Young's modulus of 100 psi or less, preferably 75 psi or less, and most preferably 50 psi or less and the base lens 850 and the first ring portion 802 has a Young's modulus of more than 100 psi, preferably more than 250 psi, and most preferably more than 350 psi. In a particularly preferred embodiment, the Young's modulus of the first ring portion 802A may be up to 500 psi.



FIG. 10B depicts the IOL 800 as being constructed by assembling at least three (3) separately molded pieces 801B, 802B and 803B. The first lens chamber 810 and the surrounding peripheral portion is provided by assembling 801B and 802B and the base lens portion 850 and the surrounding peripheral portion is provided by assembling 803B to the underside of 802B. The assembled first lens chamber 810 and surrounding peripheral portion (801B, 802B) has a lower elastic Young's modulus than the base lens portion 850 and the surrounding peripheral portion (803B). In a preferred embodiment, portions 801B, 802B has a Young's modulus of 100 psi or less, preferably 75 psi or less, and most preferably 50 psi or less and the base lens portion 803B has a Young's modulus of more than 100 psi, preferably more than 250 psi and, most preferably, more than 350 psi. In a particularly preferred embodiment, the Young's modulus of the base lens portion 803B may be up to 500 psi.


The invention described and claimed herein is not to be limited in scope by the specific preferred embodiments disclosed herein, as these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Claims
  • 1. An intraocular lens (IOL) device comprising: a first lens comprising a pair of opposing surfaces and a cavity defined therebetween, wherein the pair of opposing surfaces has at least one deformable surface;a second lens;a circumferential haptic having an outer peripheral edge, the circumferential haptic coupling the first lens and the second lens, wherein the circumferential haptic has an anterior surface and a posterior surface that are each configured to engage a lens capsule of a subject's eye, and wherein a peripheral axis parallel to a central optical axis extends from the anterior surface to the posterior surface, and wherein an uninterrupted anterior-posterior thickness along the peripheral axis and between the anterior and the posterior surfaces is greater than an anterior-posterior thickness of the second lens; anda main IOL cavity disposed between the first lens and the second lens;wherein the IOL device is resiliently biased to an unaccommodated state wherein the IOL device has a first diameter d1 in the absence of radial compressive forces exerted on the outer peripheral edge;wherein the IOL device actuates to an accommodated state wherein the IOL has a second diameter d2 in response to the radial compressive forces exerted on the outer peripheral edge, wherein d1>d2; andwherein the at least one deformable surface of the first lens is displaced away from the other opposing surface of the first lens upon application of a radial force along the circumferential haptic.
  • 2. The IOL device of claim 1, wherein the first lens is a biconvex lens.
  • 3. The IOL device of claim 1, wherein the cavity is fully enclosed.
  • 4. The IOL device of claim 1, further comprising a gel in the cavity.
  • 5. The IOL device of claim 4, wherein the gel has a refractive index of 1.46 or greater.
  • 6. The IOL device of claim 4, wherein the gel has a Young's modulus of 10 psi or less.
  • 7. The IOL device of claim 4, wherein the gel is a cross-linked vinyl-terminated phenyl siloxane polymer.
  • 8. The IOL device of claim 1, wherein the second lens is one of a plano-convex lens, a bi-convex lens, and a positive meniscus lens.
  • 9. The IOL device of claim 1, wherein the second lens is substantially more rigid than the first lens.
  • 10. The IOL device of claim 1, further comprising a hinge disposed between the circumferential haptic and the second lens, wherein the hinge is thinner than portions of the circumferential haptic and the second lens adjacent to the hinge.
  • 11. The IOL device of claim 10, wherein in the presence of the radial compressive forces on the outer peripheral edge, the hinge directs a substantial portion of the compressive forces onto the at least one deformable surface to cause a greater reduction in the first lens diameter than in the second lens diameter.
  • 12. The IOL device of claim 1, wherein the deformable surface of the first lens has a thickness on the central optical axis that is 50% or less than a thickness of the second lens on the central optical axis.
  • 13. The IOL device of claim 1, wherein the circumferential haptic comprises a plurality of radial arms coupling the second lens, the plurality of radial arms defining apertures therebetween to permit fluid communication with the main cavity.
  • 14. The IOL device of claim 1, wherein the outer peripheral edge is continuous at a radially outermost edge and configured to engage the lens capsule of the subject's eye.
  • 15. An intraocular lens (IOL) device comprising: a first lens comprising an elastic and deformable material having a first Young's modulus, the first lens comprising a pair of opposing surfaces joined together at a periphery of the first lens to define a cavity therebetween;a second lens in spaced relation to the first lens along a central optical axis;a circumferential portion encircling the first and the second lens, the circumferential portion comprising an outer peripheral edge, an anterior surface, and a posterior surface, wherein a peripheral axis parallel to the central optical axis extends from the anterior surface to the posterior surface, and wherein a continuous expanse of material of the circumferential portion along the peripheral axis has an anterior-posterior thickness between the anterior and the posterior surfaces that is greater than an anterior-posterior thickness of the second lens along the central optical axis; anda main IOL cavity defined between the first lens and the second lens;wherein at least one of a portion of the second lens and a portion of the circumferential portion is made of a material having a second Young's modulus;wherein the first Young's modulus is less than the second Young's modulus; andwherein an application of a radial force applied along the outer peripheral edge is substantially transmitted to at least one of the opposing surfaces of the first lens via a flat radial portion, causing the at least one of the opposing surfaces of the first lens to be displaced away from the second lens.
  • 16. The IOL device of claim 15, wherein only the second lens is made of the material having the second Young's modulus.
  • 17. The IOL device of claim 15, wherein only the portion of the circumferential portion is made of the material having the second Young's modulus.
  • 18. The IOL device of claim 15, wherein the first Young's modulus is 100 psi or less.
  • 19. The IOL device of claim 15, wherein the second Young's modulus is 100 psi or greater.
  • 20. The IOL device of claim 19, wherein the second Young's modulus is 150 psi or greater.
  • 21. The IOL device of claim 15, further comprising a hinge disposed between the circumferential portion and the second lens, wherein the hinge is thinner than portions of the circumferential haptic and second lens adjacent to the hinge.
  • 22. The IOL device of claim 15, wherein the at least one of the opposing surfaces comprises central and peripheral regions, the central region having a thickness that is at least 2 times greater than a thickness of the peripheral region.
  • 23. The IOL device of claim 15, wherein the flat radial portion is proximate the peripheral region of the first lens and disposed radially outward relative to a radially outermost portion of the main IOL cavity.
  • 24. An intraocular lens (IOL) device comprising: a first lens comprising opposing surfaces and a cavity defined therebetween, wherein the opposing surfaces have at least one deformable surface;a second lens;a circumferential haptic having an outer peripheral edge that is continuous at a radially outermost edge and configured to engage a lens capsule of a subject's eye, the circumferential haptic coupling the first lens and the second lens, wherein the circumferential haptic has an anterior surface and a posterior surface disposed radially inward of the outer peripheral edge; anda main IOL cavity disposed between the first lens and the second lens;wherein the IOL device is resiliently biased to an unaccommodated state wherein the IOL device has a first diameter d1 in the absence of radial compressive forces exerted on the outer peripheral edge;wherein the IOL device actuates to an accommodated state wherein the IOL device has a second diameter d2 in response to the radial compressive forces exerted on the outer peripheral edge, wherein d1>d2; andwherein the at least one deformable surface of the first lens is displaced away from the other opposing surface of the first lens upon application of the radial compressive forces.
  • 25. An intraocular lens (IOL) device comprising: a first lens comprising an elastic and deformable material, the first lens comprising opposing surfaces joined together at a peripheral region of the first lens to define a cavity therebetween;a second lens in spaced relation to the first lens along a central optical axis;a main IOL cavity defined between the first lens and the second lens;a circumferential portion encircling the first and the second lens, the circumferential portion comprising an outer peripheral edge and a flat radial portion proximate the peripheral region of the first lens, wherein the flat radial portion is disposed radially outward relative to a radially outermost portion of the main IOL cavity; andwherein an application of a radial force applied along the outer peripheral edge is substantially transmitted to at least one of the opposing surfaces of the first lens via the flat radial portion, causing the at least one of the opposing surfaces of the first lens to be displaced away from the second lens.
  • 26. The IOL device of claim 25, wherein at least a portion of the second lens and a portion of the circumferential portion is stiffer than a deformable portion of the first lens.
  • 27. The IOL device of claim 25, wherein the opposing surfaces comprise at least one deformable surface.
  • 28. The IOL device of claim 25, wherein the opposing surfaces comprise two surfaces configured to be displaced away from each other upon application of radially compressive forces.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International Patent Application No. PCT/US2014/063473 filed Oct. 31, 2014, which claims the benefit of Provisional Patent Application No. 61/899,106 filed Nov. 1, 2013, both of which are hereby incorporated by reference.

US Referenced Citations (436)
Number Name Date Kind
4032502 Lee et al. Jun 1977 A
4373218 Schachar Feb 1983 A
4512040 McClure Apr 1985 A
4585457 Kalb Apr 1986 A
4676791 LeMaster et al. Jun 1987 A
4720286 Bailey et al. Jan 1988 A
4731078 Stoy et al. Mar 1988 A
4822360 Deacon Apr 1989 A
4842601 Smith Jun 1989 A
4882368 Elias et al. Nov 1989 A
4888012 Horn et al. Dec 1989 A
4892543 Turley Jan 1990 A
4932966 Christie et al. Jul 1990 A
5035710 Nakada et al. Jul 1991 A
5059668 Fukuda et al. Oct 1991 A
5074876 Kelman Dec 1991 A
5091121 Nakada et al. Feb 1992 A
5152788 Isaacson et al. Oct 1992 A
5167883 Takemasa et al. Dec 1992 A
5171773 Chaffe et al. Dec 1992 A
5227447 Sato et al. Jul 1993 A
5236970 Christ et al. Aug 1993 A
5264522 Mize et al. Nov 1993 A
5275623 Sarfarazi Jan 1994 A
5278258 Gerace et al. Jan 1994 A
5312860 Mize et al. May 1994 A
5326506 Vanderbilt Jul 1994 A
5336487 Refojo et al. Aug 1994 A
5443506 Garabet Aug 1995 A
5447987 Sato et al. Sep 1995 A
5489302 Skottun Feb 1996 A
5583178 Oxman et al. Dec 1996 A
5607472 Thompson Mar 1997 A
5665794 Maxson et al. Sep 1997 A
5854310 Maxson Dec 1998 A
6071439 Bawa et al. Jun 2000 A
6117171 Skottun Sep 2000 A
6361561 Huo et al. Mar 2002 B1
6551354 Ghazizadeh et al. Apr 2003 B1
6616691 Tran Sep 2003 B1
6695881 Peng et al. Feb 2004 B2
6730123 Klopotek May 2004 B1
6836374 Esch et al. Dec 2004 B2
6855164 Glazier Feb 2005 B2
6858040 Nguyen et al. Feb 2005 B2
6860601 Shadduck Mar 2005 B2
6926736 Peng et al. Aug 2005 B2
6930838 Schachar Aug 2005 B2
6935743 Shadduck Aug 2005 B2
6966649 Shadduck Nov 2005 B2
6969403 Peng et al. Nov 2005 B2
7041134 Nguyen et al. May 2006 B2
7063723 Ran Jun 2006 B2
7068439 Esch et al. Jun 2006 B2
7122053 Esch Oct 2006 B2
7150760 Zhang Dec 2006 B2
7217288 Esch et al. May 2007 B2
7220279 Nun May 2007 B2
7223288 Zhang et al. May 2007 B2
7226478 Ting et al. Jun 2007 B2
7229475 Glazier Jun 2007 B2
7238201 Portney et al. Jul 2007 B2
7247168 Esch et al. Jul 2007 B2
7261737 Esch et al. Aug 2007 B2
7264351 Shadduck Sep 2007 B2
7276619 Kunzler et al. Oct 2007 B2
7278739 Shadduck Oct 2007 B2
7316713 Zhang Jan 2008 B2
7416562 Gross Aug 2008 B2
7438723 Esch Oct 2008 B2
7452377 Watling et al. Nov 2008 B2
7453646 Lo Nov 2008 B2
7485144 Esch Feb 2009 B2
7591849 Richardson Sep 2009 B2
7637947 Smith et al. Dec 2009 B2
7662179 Sarfarazi Feb 2010 B2
7675686 Lo et al. Mar 2010 B2
7753953 Yee Jul 2010 B1
7776088 Shadduck Aug 2010 B2
7780729 Nguyen et al. Aug 2010 B2
7815678 Nun Oct 2010 B2
7842087 Nun Nov 2010 B2
7854764 Nun Dec 2010 B2
7857850 Mentak et al. Dec 2010 B2
7981155 Cumming Jul 2011 B2
7985253 Cumming Jul 2011 B2
7986465 Lo et al. Jul 2011 B1
7998198 Angelopoulos et al. Aug 2011 B2
7998199 Nun Aug 2011 B2
8012204 Weinschenk, III et al. Sep 2011 B2
8018658 Lo Sep 2011 B2
8034106 Mentak et al. Oct 2011 B2
8034107 Stenger Oct 2011 B2
8038711 Clarke Oct 2011 B2
8048155 Shadduck Nov 2011 B2
8052752 Woods et al. Nov 2011 B2
8062361 Nguyen et al. Nov 2011 B2
8070806 Khoury Dec 2011 B2
8158712 Your Apr 2012 B2
8182531 Hermans et al. May 2012 B2
8187325 Zadno-Azizi et al. May 2012 B2
8197541 Schedler Jun 2012 B2
8216306 Coroneo Jul 2012 B2
8246679 Nguyen et al. Aug 2012 B2
8254034 Shields et al. Aug 2012 B1
8257827 Shi et al. Sep 2012 B1
8273123 Nun Sep 2012 B2
8303656 Shadduck Nov 2012 B2
8314927 Choi et al. Nov 2012 B2
8320049 Huang et al. Nov 2012 B2
8328869 Smiley et al. Dec 2012 B2
8361145 Scholl et al. Jan 2013 B2
8377124 Hong et al. Feb 2013 B2
8398709 Nun Mar 2013 B2
8414646 De Juan, Jr. et al. Apr 2013 B2
8425597 Glick et al. Apr 2013 B2
8425599 Shadduck Apr 2013 B2
8430928 Liao Apr 2013 B2
8447086 Hildebrand et al. May 2013 B2
8454688 Esch et al. Jun 2013 B2
8475529 Clarke Jul 2013 B2
8496701 Hermans et al. Jul 2013 B2
8500806 Phillips Aug 2013 B1
8545556 Woods et al. Oct 2013 B2
8579972 Rombach Nov 2013 B2
8585758 Woods Nov 2013 B2
8608799 Blake Dec 2013 B2
8608800 Portney Dec 2013 B2
8613766 Richardson et al. Dec 2013 B2
8647384 Lu Feb 2014 B2
8657878 Mentak et al. Feb 2014 B2
8668734 Hildebrand et al. Mar 2014 B2
8690942 Hildebrand et al. Mar 2014 B2
8715345 DeBoer et al. May 2014 B2
8715346 De Juan, Jr. et al. May 2014 B2
8734509 Mentak et al. May 2014 B2
8771347 DeBoer et al. Jul 2014 B2
8814934 Geraghty et al. Aug 2014 B2
8834565 Nun Sep 2014 B2
8858626 Noy Oct 2014 B2
8867141 Pugh et al. Oct 2014 B2
8900298 Anvar et al. Dec 2014 B2
8900300 Wortz Dec 2014 B1
8956408 Smiley et al. Feb 2015 B2
8968396 Matthews et al. Mar 2015 B2
8968399 Ghabra Mar 2015 B2
8992609 Shadduck Mar 2015 B2
9005282 Chang et al. Apr 2015 B2
9005283 Nguyen et al. Apr 2015 B2
9034035 Betser et al. May 2015 B2
9044317 Hildebrand et al. Jun 2015 B2
9072600 Tran Jul 2015 B2
9090033 Carson et al. Jul 2015 B2
9095424 Kahook et al. Aug 2015 B2
9125736 Kahook et al. Sep 2015 B2
9186244 Silvestrini et al. Nov 2015 B2
9198752 Woods Dec 2015 B2
9277987 Smiley et al. Mar 2016 B2
9277988 Chu Mar 2016 B1
9289287 Kahook et al. Mar 2016 B2
9326846 Devita Gerardi et al. May 2016 B2
9333072 Ichikawa May 2016 B2
9358103 Wortz et al. Jun 2016 B1
9364316 Kahook et al. Jun 2016 B1
9387069 Kahook et al. Jul 2016 B2
9421088 Kahook et al. Aug 2016 B1
9427312 DeBoer et al. Aug 2016 B2
9433497 DeBoer et al. Sep 2016 B2
9456895 Shadduck Oct 2016 B2
9486311 Argento et al. Nov 2016 B2
9610155 Matthews Apr 2017 B2
9622852 Simonov et al. Apr 2017 B2
9629712 Stenger Apr 2017 B2
9636213 Brady May 2017 B2
9655716 Cumming May 2017 B2
9681946 Kahook et al. Jun 2017 B2
9693858 Hildebrand et al. Jul 2017 B2
9713526 Rombach Jul 2017 B2
9713527 Nishi et al. Jul 2017 B2
9717589 Simonov et al. Aug 2017 B2
9744027 Jansen Aug 2017 B2
9744028 Simonov et al. Aug 2017 B2
9795473 Smiley et al. Oct 2017 B2
9808339 Dorronsoro Diaz et al. Nov 2017 B2
9814568 Ben Nun Nov 2017 B2
9814570 Robert et al. Nov 2017 B2
9820849 Jansen Nov 2017 B2
9848980 McCafferty Dec 2017 B2
9855137 Smiley et al. Jan 2018 B2
9855139 Matthews et al. Jan 2018 B2
9861469 Simonov et al. Jan 2018 B2
9872762 Scholl et al. Jan 2018 B2
9872763 Smiley et al. Jan 2018 B2
9877825 Kahook et al. Jan 2018 B2
9883940 Nishi et al. Feb 2018 B2
9925039 Sohn et al. Mar 2018 B2
9925040 Kahook et al. Mar 2018 B2
9931202 Borja et al. Apr 2018 B2
9987126 Borja et al. Jun 2018 B2
10004596 Brady et al. Jun 2018 B2
10028824 Kahook et al. Jul 2018 B2
10045844 Smiley et al. Aug 2018 B2
10080648 Kahook et al. Sep 2018 B2
10111745 Silvestrini et al. Oct 2018 B2
10159564 Brady et al. Dec 2018 B2
10195018 Salahieh et al. Feb 2019 B2
10195020 Matthews Feb 2019 B2
10526353 Silvestrini Jan 2020 B2
20020005344 Heidlas et al. Jan 2002 A1
20020055776 Juan, Jr. et al. May 2002 A1
20020071856 Dillingham et al. Jun 2002 A1
20020120329 Lang et al. Aug 2002 A1
20030093149 Glazier May 2003 A1
20030105522 Glazier Jun 2003 A1
20030109926 Portney Jun 2003 A1
20030149480 Shadduck Aug 2003 A1
20030158295 Fukuda et al. Aug 2003 A1
20040082993 Woods Apr 2004 A1
20040082994 Woods et al. Apr 2004 A1
20040111152 Kelman Jun 2004 A1
20040111153 Woods et al. Jun 2004 A1
20040148023 Shu Jul 2004 A1
20040162612 Portney et al. Aug 2004 A1
20040169816 Esch Sep 2004 A1
20040181279 Nun Sep 2004 A1
20040249455 Tran Dec 2004 A1
20050021139 Shadduck Jan 2005 A1
20050071002 Glazier Mar 2005 A1
20050107873 Zhou May 2005 A1
20050119740 Esch et al. Jun 2005 A1
20050137703 Chen Jun 2005 A1
20050251253 Gross Nov 2005 A1
20050251254 Brady et al. Nov 2005 A1
20050267575 Nguyen Dec 2005 A1
20060041307 Esch et al. Feb 2006 A1
20060047339 Brown Mar 2006 A1
20060069178 Rastogi et al. Mar 2006 A1
20060074487 Gilg Apr 2006 A1
20060100701 Esch et al. May 2006 A1
20060111776 Glick et al. May 2006 A1
20060134173 Liu et al. Jun 2006 A1
20060135477 Haitjema et al. Jun 2006 A1
20060155372 Coroneo Jul 2006 A1
20060212116 Woods Sep 2006 A1
20060238702 Glick et al. Oct 2006 A1
20060241752 Israel Oct 2006 A1
20070010880 Esch Jan 2007 A1
20070016293 Tran Jan 2007 A1
20070021831 Clarke Jan 2007 A1
20070032868 Woods et al. Feb 2007 A1
20070050024 Zhang Mar 2007 A1
20070050025 Nguyen et al. Mar 2007 A1
20070078515 Brady et al. Apr 2007 A1
20070088433 Esch et al. Apr 2007 A1
20070100445 Shadduck May 2007 A1
20070106377 Smith et al. May 2007 A1
20070118216 Pynson May 2007 A1
20070129798 Chawdhary Jun 2007 A1
20070129799 Schedler Jun 2007 A1
20070129800 Cumming Jun 2007 A1
20070129801 Cumming Jun 2007 A1
20070132949 Phelan Jun 2007 A1
20070185574 Nun Aug 2007 A1
20070203578 Scholl et al. Aug 2007 A1
20070213817 Esch et al. Sep 2007 A1
20070244561 Nun Oct 2007 A1
20070260308 Tran Nov 2007 A1
20070260310 Richardson Nov 2007 A1
20080004699 Nun Jan 2008 A1
20080015689 Esch et al. Jan 2008 A1
20080033547 Chang et al. Feb 2008 A1
20080046074 Smith et al. Feb 2008 A1
20080046075 Esch et al. Feb 2008 A1
20080046077 Cumming Feb 2008 A1
20080051886 Lin Feb 2008 A1
20080154364 Richardson et al. Jun 2008 A1
20080188930 Mentak et al. Aug 2008 A1
20080200982 Your Aug 2008 A1
20080269887 Cumming Oct 2008 A1
20080300680 Nun Dec 2008 A1
20080306587 Your Dec 2008 A1
20080306588 Smiley et al. Dec 2008 A1
20080306589 Donitzky et al. Dec 2008 A1
20090005865 Smiley et al. Jan 2009 A1
20090027661 Choi et al. Jan 2009 A1
20090043384 Niwa et al. Feb 2009 A1
20090116118 Frazier et al. May 2009 A1
20090125106 Weinschenk, III et al. May 2009 A1
20090149952 Shadduck Jun 2009 A1
20090198326 Zhou et al. Aug 2009 A1
20090204209 Tran Aug 2009 A1
20090204210 Pynson Aug 2009 A1
20090264998 Mentak et al. Oct 2009 A1
20090292355 Boyd et al. Nov 2009 A1
20090319040 Khoury Dec 2009 A1
20100004742 Cumming Jan 2010 A1
20100030332 Schedler Feb 2010 A1
20100055449 Ota Mar 2010 A1
20100094412 Wensrich Apr 2010 A1
20100094413 Rombach et al. Apr 2010 A1
20100121444 Nun May 2010 A1
20100131058 Shadduck May 2010 A1
20100131059 Callahan et al. May 2010 A1
20100179653 Argento et al. Jul 2010 A1
20100204787 Noy Aug 2010 A1
20100211169 Stanley et al. Aug 2010 A1
20100228344 Shadduck Sep 2010 A1
20100288346 Esch Sep 2010 A1
20100324672 Esch et al. Dec 2010 A1
20100324674 Brown Dec 2010 A1
20110029074 Reisin et al. Feb 2011 A1
20110071628 Gross et al. Mar 2011 A1
20110082544 Nun Apr 2011 A1
20110112636 Nun May 2011 A1
20110118834 Lo et al. May 2011 A1
20110118836 Jain May 2011 A1
20110160852 Mentak et al. Jun 2011 A1
20110208301 Anvar et al. Aug 2011 A1
20110224788 Webb Sep 2011 A1
20110282442 Scholl et al. Nov 2011 A1
20110288638 Smiley et al. Nov 2011 A1
20120016473 Brady et al. Jan 2012 A1
20120035724 Clarke Feb 2012 A1
20120071972 Zhao Mar 2012 A1
20120078361 Shadduck Mar 2012 A1
20120078364 Stenger Mar 2012 A1
20120095125 Hu et al. Apr 2012 A1
20120150292 Mentak et al. Jun 2012 A1
20120232649 Cuevas Sep 2012 A1
20120245683 Christie et al. Sep 2012 A1
20120253458 Geraghty et al. Oct 2012 A1
20120253459 Reich et al. Oct 2012 A1
20120290084 Coroneo Nov 2012 A1
20120296423 Caffey Nov 2012 A1
20120296424 Betser Nov 2012 A1
20120310341 Simonov et al. Dec 2012 A1
20120310343 Van Noy Dec 2012 A1
20130006353 Betser et al. Jan 2013 A1
20130018461 Nun Jan 2013 A1
20130035760 Portney Feb 2013 A1
20130038944 Chang et al. Feb 2013 A1
20130060331 Shadduck Mar 2013 A1
20130110234 DeVita et al. May 2013 A1
20130110235 Shweigerling May 2013 A1
20130116781 Nun May 2013 A1
20130131794 Smiley et al. May 2013 A1
20130190867 Peyman Jul 2013 A1
20130226295 De Juan, Jr. et al. Aug 2013 A1
20130231741 Clarke Sep 2013 A1
20130250239 Hildebrand et al. Sep 2013 A1
20130268070 Esch et al. Oct 2013 A1
20130297018 Brady et al. Nov 2013 A1
20130317607 DeBoer et al. Nov 2013 A1
20130317608 Hermans et al. Nov 2013 A1
20140012277 Matthews et al. Jan 2014 A1
20140058507 Reich et al. Feb 2014 A1
20140085726 Portney Mar 2014 A1
20140100654 Portney et al. Apr 2014 A1
20140107459 Lind et al. Apr 2014 A1
20140111765 DeBoer et al. Apr 2014 A1
20140121768 Simpson May 2014 A1
20140135917 Glazier May 2014 A1
20140135918 De Juan, Jr. et al. May 2014 A1
20140142558 Culbertson et al. May 2014 A1
20140172092 Carson et al. Jun 2014 A1
20140180404 Tram Jun 2014 A1
20140180405 Weinschenk, III et al. Jun 2014 A1
20140180406 Simpson Jun 2014 A1
20140180407 Sohn et al. Jun 2014 A1
20140180410 Gerardi Jun 2014 A1
20140227437 DeBoer et al. Aug 2014 A1
20140228949 Argento et al. Aug 2014 A1
20140249625 Shadduck Sep 2014 A1
20140257478 McCafferty Sep 2014 A1
20140257479 McCafferty Sep 2014 A1
20140309734 Sohn et al. Oct 2014 A1
20150087743 Anvar et al. Mar 2015 A1
20150105760 Rao et al. Apr 2015 A1
20150127102 Wortz May 2015 A1
20150173892 Borja et al. Jun 2015 A1
20150202041 Shadduck Jul 2015 A1
20150216652 Jansen Aug 2015 A1
20150238310 Matthews et al. Aug 2015 A1
20150366656 Wortz et al. Dec 2015 A1
20160000558 Honigsbaum Jan 2016 A1
20160008126 Salahieh et al. Jan 2016 A1
20160051361 Phillips Feb 2016 A1
20160058553 Salahieh et al. Mar 2016 A1
20160074154 Woods Mar 2016 A1
20160184089 Dudee et al. Jun 2016 A1
20160184092 Smiley et al. Jun 2016 A1
20160208138 Nishijima et al. Jul 2016 A1
20160256265 Borja et al. Sep 2016 A1
20160262875 Smith et al. Sep 2016 A1
20160281019 Deklippel et al. Sep 2016 A1
20160287380 Shi et al. Oct 2016 A1
20170020662 Shadduck Jan 2017 A1
20170049561 Smiley et al. Feb 2017 A1
20170049562 Argento et al. Feb 2017 A1
20170216021 Brady Aug 2017 A1
20170247525 Silverstrini et al. Aug 2017 A1
20170290658 Hildebrand et al. Oct 2017 A1
20170319332 Kahook et al. Nov 2017 A1
20170342096 Silvestrini Nov 2017 A1
20170348095 Wortz et al. Dec 2017 A1
20180014928 Kahook et al. Jan 2018 A1
20180028308 Smiley et al. Feb 2018 A1
20180110613 Wortz et al. Apr 2018 A1
20180125640 Smiley et al. May 2018 A1
20180132997 Smiley et al. May 2018 A1
20180147051 Scholl et al. May 2018 A1
20180153682 Hajela et al. Jun 2018 A1
20180161152 Argento et al. Jun 2018 A1
20180161153 Kahook et al. Jun 2018 A1
20180177589 Argento et al. Jun 2018 A1
20180177639 Rao et al. Jun 2018 A1
20180256315 Hildebrand et al. Sep 2018 A1
20180271642 Wortz et al. Sep 2018 A1
20180271645 Brady et al. Sep 2018 A1
20180280135 Otts Oct 2018 A1
20180296323 Olcina Portilla Oct 2018 A1
20180307061 State et al. Oct 2018 A1
20180318068 Otts et al. Nov 2018 A1
20180344453 Brady Dec 2018 A1
20180368971 Zacher et al. Dec 2018 A1
20180368973 Wortz et al. Dec 2018 A1
20180368974 Kahook et al. Dec 2018 A1
20190000612 Rao et al. Jan 2019 A1
20190015198 Kuiper Jan 2019 A1
20190021848 Kahook et al. Jan 2019 A1
20190069989 Otts et al. Mar 2019 A1
20190076239 Wortz et al. Mar 2019 A1
20190076243 Hadba et al. Mar 2019 A1
20190083235 Wortz Mar 2019 A1
20190099263 Brady et al. Apr 2019 A1
20190374334 Brady et al. Dec 2019 A1
Foreign Referenced Citations (69)
Number Date Country
20 2010 003217 Aug 2011 DE
0356050 Feb 1990 EP
0766540 Aug 1999 EP
1881818 Jul 2015 EP
H09-150002 Jun 1997 JP
2001-525220 Dec 2001 JP
2005-511201 Apr 2005 JP
2006-511245 Apr 2006 JP
2006-516002 Jun 2006 JP
2010-514507 May 2010 JP
2011-502713 Jan 2011 JP
2013-047290 Mar 2013 JP
WO 9217132 Oct 1992 WO
WO 9929266 Jun 1999 WO
WO 2001034067 May 2001 WO
WO 2004037127 May 2004 WO
WO 2004052242 Jun 2004 WO
WO 2004054471 Jul 2004 WO
WO 2004072689 Aug 2004 WO
WO 2006047383 May 2006 WO
WO 2007005778 Jan 2007 WO
WO 2007047529 Apr 2007 WO
WO 2007047530 Apr 2007 WO
WO 2008024766 Feb 2008 WO
WO 2008031231 Mar 2008 WO
WO 2008077040 Jun 2008 WO
WO 2008082957 Jul 2008 WO
WO 2008103798 Aug 2008 WO
WO 2009015161 Jan 2009 WO
WO 2009015234 Jan 2009 WO
WO 2009015240 Jan 2009 WO
WO2009015226 Jan 2009 WO
WO 2009064876 May 2009 WO
WO 2010010565 Jan 2010 WO
WO 2010081093 Jul 2010 WO
WO 2011026068 Mar 2011 WO
WO 2011106435 Sep 2011 WO
WO2011137191 Nov 2011 WO
WO 2012006616 Jan 2012 WO
WO 2012129407 Sep 2012 WO
WO2013016804 Feb 2013 WO
WO 2013070924 May 2013 WO
WO 2013142323 Sep 2013 WO
WO 2013166068 Nov 2013 WO
WO 2013180254 Dec 2013 WO
WO 2013190130 Dec 2013 WO
WO 2014099630 Jun 2014 WO
WO 2014145562 Sep 2014 WO
WO 2014152017 Sep 2014 WO
WO 2014197170 Dec 2014 WO
WO 2015066502 May 2015 WO
WO 2015066532 May 2015 WO
WO 2015126604 Aug 2015 WO
WO 2016018932 Feb 2016 WO
WO 2016033217 Mar 2016 WO
WO 2016122805 Aug 2016 WO
WO 2016201351 Dec 2016 WO
WO 2017079449 May 2017 WO
WO 2017079733 May 2017 WO
WO 2017087358 May 2017 WO
WO 2017096087 Jun 2017 WO
WO 2017192855 Nov 2017 WO
WO 2018081595 May 2018 WO
WO 2018119408 Jun 2018 WO
WO 2018167099 Sep 2018 WO
WO 2018222579 Dec 2018 WO
WO 2018227014 Dec 2018 WO
WO 2019005859 Jan 2019 WO
WO 2019027845 Feb 2019 WO
Non-Patent Literature Citations (13)
Entry
Ehrmann, et al., “Biomechanical analysis of the accommodative apparatus in primates”, Clinical and Experimental Optometry, May 2008, vol. 91, Issue 3, pp. 302-312.
Ehrmann, et al., “Ex Vivo Accommodation Simulator II—Concept and Preliminary Results”, Proceedings of SPIE vol. 5314, Ophthalmic Technologies XIV, Jul. 2004, pp. 48-58.
Gabel, et al., “Silicone oil with high specific gravity for intraocular use”, British Journal of Ophthalmology, Apr. 1987, vol. 71, 262-267.
Ghallagher-Wetmore, et al., “Supercritical fluid processing: a new dry technique for photoresist developing”, SPIE's 1995 Symposium on Microlithography, 1995, vol. 2438, 16 pages.
Lane, et al., “Comparison of the biomechanical behavior of foldable intraocular lenses”, Journal of Cataract Refract Surg, Nov. 2004, vol. 30, pp. 2397-2402.
Nakamura, et al., “Analysis and Fractionation of Silicone and Fluorosilicone Oils for Intraocular Use”, Investigative Ophthalmology & Visual Science, vol. 31, No. 10, Oct. 1990, 2059-2069.
National Center for Biotechnology Information. PubChem Substance Database; SID=184590955, https://pubchem.ncbi.nlm.nih.gov/substance/184590955 (accessed Sep. 20, 2017).
Zhang, et al., “Fluidic adaptive lens with high focal length tunability”, Applied Physics Letters, May 2003, vol. 82, No. 19, pp. 3171-3172.
Zhang, et al., “Integrated fluidic adaptive zoom lens”, Optics Letters, Dec. 2004, vol. 29, No. 24, pp. 2855-2857.
Zhao, et al., “Strategies for Supercritical CO2 Fractionation of Polydimethylsiloxane,” Journal of Applied Polymer Science, 1995, vol. 55, 773-778.
Aliancy, et al., “Long-term capsule clarity with a disk-shaped intraocular lens”, Journal of Cataract & Refractive Surgery, Apr. 2018, vol. 44, Issue 4, pp. 504-509.
Kramer, et al., “Prevention of postoperative capsular bag opacification using intraocular lenses and endocapsular devices maintaining an open or expanded capsular bag”, Journal of Cataract & Refractive Surgery, Mar. 2016, vol. 42, Issue 3, pp. 469-484.
Leishman, et al., “Prevention of capsular bag opacification with a modified hydrophilic acrylic disk-shaped intraocular lens”, Journal of Cataract & Refractive Surgery, Sep. 2012, vol. 38, Issue 9, pp. 1664-1670.
Related Publications (1)
Number Date Country
20160317287 A1 Nov 2016 US
Provisional Applications (1)
Number Date Country
61899106 Nov 2013 US
Continuations (1)
Number Date Country
Parent PCT/US2014/063473 Oct 2014 US
Child 15144568 US